These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 30693676)
21. Conformational transition in the substrate binding domain of β-secretase exploited by NMA and its implication in inhibitor recognition: BACE1-myricetin a case study. Chakraborty S; Kumar S; Basu S Neurochem Int; 2011 Jul; 58(8):914-23. PubMed ID: 21354237 [TBL] [Abstract][Full Text] [Related]
22. Discovery of biphenylacetamide-derived inhibitors of BACE1 using de novo structure-based molecular design. Mok NY; Chadwick J; Kellett KA; Casas-Arce E; Hooper NM; Johnson AP; Fishwick CW J Med Chem; 2013 Mar; 56(5):1843-52. PubMed ID: 23374014 [TBL] [Abstract][Full Text] [Related]
23. Design and synthesis of thiophene dihydroisoquinolines as novel BACE1 inhibitors. Xu YZ; Yuan S; Bowers S; Hom RK; Chan W; Sham HL; Zhu YL; Beroza P; Pan H; Brecht E; Yao N; Lougheed J; Yan J; Tam D; Ren Z; Ruslim L; Bova MP; Artis DR Bioorg Med Chem Lett; 2013 May; 23(10):3075-80. PubMed ID: 23570791 [TBL] [Abstract][Full Text] [Related]
24. Synthesis, in vitro biological evaluation and molecular docking studies of benzimidamides as potential BACE1 inhibitors. Niu Y; Gao H; Xu F; Wang C; Liu P; Yang G; Sun Q; Xu P Chem Biol Drug Des; 2012 Nov; 80(5):775-80. PubMed ID: 22882897 [TBL] [Abstract][Full Text] [Related]
25. Synthesis of morpholine derivatives using the Castagnoli-Cushman reaction as BACE1 inhibitors: Unexpected binding activity of cyclic thioamides. Calugi L; Lenci E; Innocenti R; Trabocchi A Bioorg Med Chem Lett; 2020 Jul; 30(13):127211. PubMed ID: 32354570 [TBL] [Abstract][Full Text] [Related]
26. Fragment-based designing for the generation of novel leads against BACE1. Das S; Chakraborty S; Basu S Cent Nerv Syst Agents Med Chem; 2015; 15(1):52-64. PubMed ID: 25625854 [TBL] [Abstract][Full Text] [Related]
27. Inhibition of BACE1 Activity by a DNA Aptamer in an Alzheimer's Disease Cell Model. Liang H; Shi Y; Kou Z; Peng Y; Chen W; Li X; Li S; Wang Y; Wang F; Zhang X PLoS One; 2015; 10(10):e0140733. PubMed ID: 26473367 [TBL] [Abstract][Full Text] [Related]
28. Structure-Based Survey of the Binding Modes of BACE1 Inhibitors. Hu H; Chen Z; Xu X; Xu Y ACS Chem Neurosci; 2019 Feb; 10(2):880-889. PubMed ID: 30540177 [TBL] [Abstract][Full Text] [Related]
29. Design and synthesis of bicyclic acetals as Beta Secretase (BACE1) inhibitors. Innocenti R; Lenci E; Menchi G; Pupi A; Trabocchi A Bioorg Med Chem; 2017 Oct; 25(19):5077-5083. PubMed ID: 28359674 [TBL] [Abstract][Full Text] [Related]
30. Discovery of imidazopyridines containing isoindoline-1,3-dione framework as a new class of BACE1 inhibitors: Design, synthesis and SAR analysis. Azimi S; Zonouzi A; Firuzi O; Iraji A; Saeedi M; Mahdavi M; Edraki N Eur J Med Chem; 2017 Sep; 138():729-737. PubMed ID: 28728105 [TBL] [Abstract][Full Text] [Related]
31. Identification of Novel BACE1 Inhibitors by Combination of Pharmacophore Modeling, Structure-Based Design and In Vitro Assay. Ju Y; Li Z; Deng Y; Tong A; Zhou L; Luo Y Curr Comput Aided Drug Des; 2016; 12(1):73-82. PubMed ID: 26899408 [TBL] [Abstract][Full Text] [Related]
32. Conformational restriction approach to β-secretase (BACE1) inhibitors III: effective investigation of the binding mode by combinational use of X-ray analysis, isothermal titration calorimetry and theoretical calculations. Yonezawa S; Fujiwara K; Yamamoto T; Hattori K; Yamakawa H; Muto C; Hosono M; Tanaka Y; Nakano T; Takemoto H; Arisawa M; Shuto S Bioorg Med Chem; 2013 Nov; 21(21):6506-22. PubMed ID: 24051074 [TBL] [Abstract][Full Text] [Related]
33. Identification of new BACE1 inhibitors using Pharmacophore and Molecular dynamics simulations approach. Dhanabalan AK; Kesherwani M; Velmurugan D; Gunasekaran K J Mol Graph Model; 2017 Sep; 76():56-69. PubMed ID: 28710924 [TBL] [Abstract][Full Text] [Related]
34. Identification of BACE1 inhibitors from Panax ginseng saponins-An Insilco approach. Karpagam V; Sathishkumar N; Sathiyamoorthy S; Rasappan P; Shila S; Kim YJ; Yang DC Comput Biol Med; 2013 Sep; 43(8):1037-44. PubMed ID: 23816176 [TBL] [Abstract][Full Text] [Related]
35. Synthesis, characterization, and PK/PD studies of a series of spirocyclic pyranochromene BACE1 inhibitors. Volgraf M; Chan L; Huestis MP; Purkey HE; Burkard M; Geck Do M; Harris J; Hunt KW; Liu X; Lyssikatos JP; Rana S; Thomas AA; Vigers GP; Siu M Bioorg Med Chem Lett; 2014 Jun; 24(11):2477-80. PubMed ID: 24780121 [TBL] [Abstract][Full Text] [Related]
36. Small-molecule BACE1 inhibitors: a patent literature review (2006 - 2011). Probst G; Xu YZ Expert Opin Ther Pat; 2012 May; 22(5):511-40. PubMed ID: 22512789 [TBL] [Abstract][Full Text] [Related]
37. Molecular modeling, synthesis, and activity studies of novel biaryl and fused-ring BACE1 inhibitors. Chirapu SR; Pachaiyappan B; Nural HF; Cheng X; Yuan H; Lankin DC; Abdul-Hay SO; Thatcher GR; Shen Y; Kozikowski AP; Petukhov PA Bioorg Med Chem Lett; 2009 Jan; 19(1):264-74. PubMed ID: 19013792 [TBL] [Abstract][Full Text] [Related]
38. Tripeptidic BACE1 inhibitors devised by in-silico conformational structure-based design. Hamada Y; Tagad HD; Nishimura Y; Ishiura S; Kiso Y Bioorg Med Chem Lett; 2012 Jan; 22(2):1130-5. PubMed ID: 22178553 [TBL] [Abstract][Full Text] [Related]
39. Inhibitory activities of major anthraquinones and other constituents from Cassia obtusifolia against β-secretase and cholinesterases. Jung HA; Ali MY; Jung HJ; Jeong HO; Chung HY; Choi JS J Ethnopharmacol; 2016 Sep; 191():152-160. PubMed ID: 27321278 [TBL] [Abstract][Full Text] [Related]
40. The selective BACE1 inhibitor VIa reduces amyloid-β production in cell and mouse models of Alzheimer's disease. Cheng X; Zhou Y; Gu W; Wu J; Nie A; Cheng J; Zhou J; Zhou W; Zhang Y J Alzheimers Dis; 2013; 37(4):823-34. PubMed ID: 23948917 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]